Related references
Note: Only part of the references are listed.Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older: United States, 2015
David K. Kim et al.
ANNALS OF INTERNAL MEDICINE (2015)
The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor
Leslie R. Harrold et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy
Huifeng Yun et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study
P. Emery et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial
Michael Schiff et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
TNF INHIBITOR THERAPY AND RISK OF BREAST CANCER RECURRENCE IN PATIENTS WITH RHEUMATOID ARTHRITIS-A NATIONWIDE COHORT STUDY
P. Raaschou et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Safety of Etanercept and Methotrexate in Patients with Rheumatoid Arthritis and Hepatitis C Virus Infection: A Multicenter Randomized Clinical Trial
Florenzo Iannone et al.
JOURNAL OF RHEUMATOLOGY (2014)
Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial
Hideto Kameda et al.
Modern Rheumatology (2014)
Which subgroup of rheumatoid arthritis patients benefits from switching to tocilizumab versus etanercept after previous infliximab failure? A retrospective study
Hiroki Wakabayashi et al.
Modern Rheumatology (2014)
Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial
Josef S. Smolen et al.
LANCET (2014)
Management of patients with hepatitis B who require immunosuppressive therapy
Jessica P. Hwang et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2014)
Tofacitinib versus Methotrexate in Rheumatoid Arthritis
Eun Bong Lee et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Sustained Remission with Etanercept Tapering in Early Rheumatoid Arthritis
Paul Emery et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Association of Higher Methotrexate Dose With Lymphoproliferative Disease Onset in Rheumatoid Arthritis Patients
Tomohiro Kameda et al.
ARTHRITIS CARE & RESEARCH (2014)
Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis A Randomized Trial
Joel Kremer et al.
ANNALS OF INTERNAL MEDICINE (2013)
Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial
P. H. de Jong et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2)
Frank Buttgereit et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study
Michael E. Weinblatt et al.
ARTHRITIS AND RHEUMATISM (2013)
Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-fourmonth phase III randomized radiographic study
Desiree van der Heijde et al.
ARTHRITIS AND RHEUMATISM (2013)
The Influence of Anti-TNF Therapy on the Course of Chronic Hepatitis C Virus Infection in Patients with Inflammatory Bowel Disease
Ming Valerie Lin et al.
DIGESTIVE DISEASES AND SCIENCES (2013)
GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes
Gordon Guyatt et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2013)
GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength
Jeffrey C. Andrews et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2013)
GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations
Jeff Andrews et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2013)
Randomized Controlled Trial of Entecavir Prophylaxis for Rituximab-Associated Hepatitis B Virus Reactivation in Patients With Lymphoma and Resolved Hepatitis B
Yi-Hsiang Huang et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
Cem Gabay et al.
LANCET (2013)
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
Gerd R. Burmester et al.
LANCET (2013)
Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial
Josef S. Smolen et al.
LANCET (2013)
Therapies for Active Rheumatoid Arthritis after Methotrexate Failure
James R. O'Dell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Incidence of tuberculosis among anti-tumor necrosis factor users in patients with a previous history of tuberculosis
Kyung-Wook Jo et al.
RESPIRATORY MEDICINE (2013)
Rituximab versus anti-TNF in patients who previously failed one TNF inhibitor in an observational cohort
K. Chatzidionysiou et al.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2013)
Risk of infections in rheumatoid arthritis patients switching from anti-TNF agents to rituximab, abatacept, or another anti-TNF agent, a retrospective administrative claims analysis
Stephen S. Johnston et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2013)
Tumor necrosis factor-α inhibitors and chronic hepatitis C: A comprehensive literature review
Maurizio Pompili et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2013)
Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden
Pauline Raaschou et al.
BMJ-BRITISH MEDICAL JOURNAL (2013)
Non-randomized studies as a source of complementary, sequential or replacement evidence for randomized controlled trials in systematic reviews on the effects of interventions
Holger J. Schuenemann et al.
RESEARCH SYNTHESIS METHODS (2013)
Low-Dose Prednisone Inclusion in a Methotrexate-Based, Tight Control Strategy for Early Rheumatoid Arthritis A Randomized Trial
Marije F. Bakker et al.
ANNALS OF INTERNAL MEDICINE (2012)
Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study
Juan J. Gomez-Reino et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
A Phase IIb Dose-Ranging Study of the Oral JAK Inhibitor Tofacitinib (CP-690,550) Versus Placebo in Combination With Background Methotrexate in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone
Joel M. Kremer et al.
ARTHRITIS AND RHEUMATISM (2012)
Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs
Roy Fleischmann et al.
ARTHRITIS AND RHEUMATISM (2012)
A Randomized Comparative Effectiveness Study of Oral Triple Therapy Versus Etanercept Plus Methotrexate in Early Aggressive Rheumatoid Arthritis The Treatment of Early Aggressive Rheumatoid Arthritis Trial
Larry W. Moreland et al.
ARTHRITIS AND RHEUMATISM (2012)
Association Between Vaccination for Herpes Zoster and Risk of Herpes Zoster Infection Among Older Patients With Selected Immune-Mediated Diseases
Jie Zhang et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial
Ronald F. van Vollenhoven et al.
LANCET (2012)
Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
Roy Fleischmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
Ronald F. van Vollenhoven et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Tuberculosis infection in rheumatic patients with infliximab therapy: experience with 157 patients
Christiane Aguiar Nobre et al.
RHEUMATOLOGY INTERNATIONAL (2012)
Rheumatoid Arthritis Disease Activity Measures: American College of Rheumatology Recommendations for Use in Clinical Practice
Jaclyn Anderson et al.
ARTHRITIS CARE & RESEARCH (2012)
2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis
Jasvinder A. Singh et al.
ARTHRITIS CARE & RESEARCH (2012)
Low-dose oral prednisone improves clinical and ultrasonographic remission rates in early rheumatoid arthritis: results of a 12-month open-label randomised study
Carlomaurizio Montecucco et al.
ARTHRITIS RESEARCH & THERAPY (2012)
Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports
A. M. Evens et al.
ANNALS OF ONCOLOGY (2011)
Pneumococcal antibody levels after pneumovax in patients with rheumatoid arthritis on methotrexate
Elizabeth Coulson et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy
Joung-Liang Lan et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors
Meliha Crnkic Kapetanovic et al.
ARTHRITIS AND RHEUMATISM (2011)
Significant improvement in synovitis, osteitis, and bone erosion following golimumab and methotrexate combination therapy as compared with methotrexate alone: A magnetic resonance imaging study of 318 methotrexate-naive rheumatoid arthritis patients
Mikkel Ostergaard et al.
ARTHRITIS AND RHEUMATISM (2011)
American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials
David T. Felson et al.
ARTHRITIS AND RHEUMATISM (2011)
GRADE guidelines: 2. Framing the question and deciding on important outcomes
Gordon H. Guyatt et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2011)
Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts
Akihiro Tamori et al.
JOURNAL OF GASTROENTEROLOGY (2011)
Tocilizumab Monotherapy Reduces Arterial Stiffness as Effectively as Etanercept or Adalimumab Monotherapy in Rheumatoid Arthritis: An Open-label Randomized Controlled Trial
Kensuke Kume et al.
JOURNAL OF RHEUMATOLOGY (2011)
Hepatitis B Virus (HBV) Reactivation in Patients Receiving Tumor Necrosis Factor (TNF)-Targeted Therapy Analysis of 257 Cases
Roberto Perez-Alvarez et al.
MEDICINE (2011)
Phase II Study of Tofacitinib (CP-690,550) Combined With Methotrexate in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Yoshiya Tanaka et al.
ARTHRITIS CARE & RESEARCH (2011)
The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study
Jie Zhang et al.
ARTHRITIS RESEARCH & THERAPY (2011)
Early disease control by low-dose prednisone comedication may affect the quality of remission in patients with early rheumatoid arthritis
Monica Todoerti et al.
NEUROENDOCRINE IMMUNOLOGY IN RHEUMATIC DISEASES: TRANSLATION FROM BASICS TO CLINICS (2010)
Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?
A. Finckh et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Immunization Responses in Rheumatoid Arthritis Patients Treated With Rituximab Results From a Controlled Clinical Trial
Clifton O. Bingham et al.
ARTHRITIS AND RHEUMATISM (2010)
Golimumab, a New Human Anti-Tumor Necrosis Factor α Antibody, Administered Intravenously in Patients With Active Rheumatoid Arthritis Forty-Eight-Week Efficacy and Safety Results of a Phase III Randomized, Double-Blind, Placebo-Controlled Study
Joel Kremer et al.
ARTHRITIS AND RHEUMATISM (2010)
2010 Rheumatoid Arthritis Classification Criteria An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative
Daniel Aletaha et al.
ARTHRITIS AND RHEUMATISM (2010)
Safety of rituximab in rheumatoid arthritis patients with a history of severe or recurrent bacterial infection: Observational study of 30 cases in everyday practice
Eric Toussirot et al.
JOINT BONE SPINE (2010)
Influence of Anti-Tumor Necrosis Factor Therapy on Cancer Incidence in Patients With Rheumatoid Arthritis Who Have Had a Prior Malignancy: Results From the British Society for Rheumatology Biologics Register
W. G. Dixon et al.
ARTHRITIS CARE & RESEARCH (2010)
Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study
E. C. Keystone et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Efficacy and Tolerability of Rituximab With or Without PEGylated Interferon Alfa-2b Plus Ribavirin in Severe Hepatitis C Virus-Related Vasculitis
Benjamin Terrier et al.
ARTHRITIS AND RHEUMATISM (2009)
Golimumab, a Human Anti-Tumor Necrosis Factor α Monoclonal Antibody, Injected Subcutaneously Every Four Weeks in Methotrexate-Naive Patients With Active Rheumatoid Arthritis Twenty-Four-Week Results of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Golimumab Before Methotrexate as First-Line Therapy for Early-Onset Rheumatoid Arthritis
Paul Emery et al.
ARTHRITIS AND RHEUMATISM (2009)
Use of tumor necrosis factor-α (TNF-α) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients
Sophia Li et al.
CLINICAL RHEUMATOLOGY (2009)
Chronic Hepatitis B: Update 2009
Anna S. F. Lok et al.
HEPATOLOGY (2009)
Safety of Etanercept in Patients at High Risk for Mycobacterial Tuberculosis Infections
Rohit Aggarwal et al.
JOURNAL OF RHEUMATOLOGY (2009)
Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate
M. Schiff et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Triple therapy in early active rheumatoid arthritis
S. A. Saunders et al.
ARTHRITIS AND RHEUMATISM (2008)
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis
Kenneth G. Saag et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2008)
Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases
I. Cavazzana et al.
AUTOIMMUNITY REVIEWS (2008)
Long-term follow-up of patients with tuberculosis as a complication of tumour necrosis factor (TNF)-α antagonist therapy:: safe re-initiation of TNF-α blockers after appropriate anti-tuberculous treatment
B. Denis et al.
CLINICAL MICROBIOLOGY AND INFECTION (2008)
GRADE:: going from evidence to recommendations
Gordon H. Guyatt et al.
BMJ-BRITISH MEDICAL JOURNAL (2008)
GRADE:: an emerging consensus on rating quality of evidence and strength of recommendations
Gordon H. Guyatt et al.
BRITISH MEDICAL JOURNAL (2008)
Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis
E. H. S. Choy et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease
E. J. Cepeda et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trial
Chiun Hsu et al.
HEPATOLOGY (2008)
Estimates of the prevalence of arthritis and other rheumatic conditions in the United States
Charles G. Helmick et al.
ARTHRITIS AND RHEUMATISM (2008)
Treatment of early rheumatoid arthritis
Patrick Durez et al.
ARTHRITIS AND RHEUMATISM (2007)
Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial)
S. M. M. Verstappen et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
A practical guide to scoring a Multi-Dimensional Health Assessment Questionnaire (MDHAQ) and Routine Assessment of Patient Index Data (RAPID) scores in 10-20 seconds for use in standard clinical care, without rulers, calculators, websites or computers
Theodore Pincus et al.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2007)
B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents
Axel Finckh et al.
ARTHRITIS AND RHEUMATISM (2007)
Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study
Hilary A. Capell et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus
H. Marotte et al.
RHEUMATOLOGY (2007)
Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study
P. L. C. M. van Riel et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Safety of anti-TNF-α therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis
C. H. Roux et al.
RHEUMATOLOGY (2006)
Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison
B. Combe et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy
W Yeo et al.
HEPATOLOGY (2006)
A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization
JW Jang et al.
HEPATOLOGY (2006)
The definition and measurement of disease modification in inflammatory rheumatic diseases
D Aletaha et al.
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA (2006)
Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis
MC Kapetanovic et al.
RHEUMATOLOGY (2006)
The disease activity score is not suitable as the sole criterion for initiation and evaluation of anti-tumor necrosis factor therapy in the clinic - Discordance between assessment measures and limitations in questionnaire use for regulatory purposes
F Wolfe et al.
ARTHRITIS AND RHEUMATISM (2005)
Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years - A multicenter, double-blind, placebo-controlled trial
S Wassenberg et al.
ARTHRITIS AND RHEUMATISM (2005)
Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate -: A two-year randomized trial
B Svensson et al.
ARTHRITIS AND RHEUMATISM (2005)
Remission and active disease in rheumatoid arthritis - Defining criteria for disease activity states
D Aletaha et al.
ARTHRITIS AND RHEUMATISM (2005)
Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial
J Fransen et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
A two year randomised controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying antirheumatic drugs
EH Choy et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study
NN Zein
JOURNAL OF HEPATOLOGY (2005)
Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score
D Aletaha et al.
ARTHRITIS RESEARCH & THERAPY (2005)
Targeted anticytokine therapy in patients with chronic heart failure - Results of the Randomized Etanercept Worldwide evALuation (RENEWAL)
DL Mann et al.
CIRCULATION (2004)
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial
L Klareskog et al.
LANCET (2004)
The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis
O Elkayam et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2004)
Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial
C Grigor et al.
LANCET (2004)
Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis
DM Gerlag et al.
ARTHRITIS AND RHEUMATISM (2004)
Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial
HA Capell et al.
ANNALS OF THE RHEUMATIC DISEASES (2004)
A randomised placebo controlled 12 week trial of budesonide and prednisolone in rheumatoid arthritis
JR Kirwan et al.
ANNALS OF THE RHEUMATIC DISEASES (2004)
Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection
FA Parke et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2004)
Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure -: Results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial
ES Chung et al.
CIRCULATION (2003)
Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis
DH Solomon et al.
CIRCULATION (2003)
A simplified disease activity index for rheumatoid arthritis for use in clinical practice
JS Smolen et al.
RHEUMATOLOGY (2003)
Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection
JR Peterson et al.
ANNALS OF THE RHEUMATIC DISEASES (2003)
Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy
GKK Lau et al.
GASTROENTEROLOGY (2003)
Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate - A randomized, double-blind, placebo-controlled trial
JM Kremer et al.
ANNALS OF INTERNAL MEDICINE (2002)
Low-dose prednisone therapy for patients with early active rheumatoid arthritis: Clinical efficacy, disease-modifying properties, and side effects - A randomized, double-blind, placebo-controlled clinical trial
AA van Everdingen et al.
ANNALS OF INTERNAL MEDICINE (2002)
Share Paper
